Fines, But No Prison Time For Ex-Acclarent Execs
Executive Summary
The sentences are the latest chapter in a long-running off-label marketing case.
You may also be interested in...
Integra Buys Acclarent From J&J To Expand ENT 'Footprint'
Integra will pay $275m in cash plus $5m more in potential milestone incentive payments to add Acclarent’s ear, nose, and throat surgery devices to its existing neurosurgery portfolio.
Financial Penalties, COVID-19 Liability Top FDLI List Of Top Medtech Lawsuits
The report outlines the lawsuits that the Food and Drug Law Institute believes could have the greatest impacts on industries regulated by the US FDA.
Court Upholds Acclarent Off-Label Marketing Convictions
The judge agreed that off-label marketing cases pose some challenges, but said the evidence against the former Acclarent execs was strong.